Table 2. Association between DAPK expression (percent positivity) in tumor center, front and tumor buds with clinicopathological features.
| Feature | Center (n = 144) | P-value | Front (n = 134) | P-value | Buds (n = 91) | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean ± SD | N | Mean ± SD | N | Mean ± SD | |||||
| Gender (n = 144) | Male | 66 | 72.2 ± 18.9 | 0.0334 | 62 | 74.1 ± 18.5 | 0.2751 | 42 | 39.7 ± 22.1 | 0.63 |
| Female | 78 | 79.9 ± 10.7 | 72 | 70.3 ± 20.5 | 49 | 37.6 ± 21.7 | ||||
| Patient age (n = 144) (years) | Corr. coeff | 144 | −0.073 | 0.3871 | 134 | −0.14 | 0.1061 | 91 | −0.035 | 0.736 |
| Tumor size (n = 144) (cm) | Corr. coeff | 144 | −0.036 | 0.6654 | 134 | −0.077 | 0.3752 | 91 | −0.007 | 0.945 |
| Histological subtype (n = 144) | Other | 130 | 75.7 ± 16.0 | 0.1649 | 121 | 73.0 ± 19.5 | 0.0445 | 81 | 38.5 ± 21.4 | 0.939 |
| Mucinous | 14 | 82.8 ± 7.0 | 13 | 62.9 ± 18.1 | 10 | 39.5 ± 25.9 | ||||
| Tumor grade (n = 144) | G1–2 | 97 | 75.4 ± 15.8 | 0.2106 | 90 | 74.3 ± 16.7 | 0.3123 | 63 | 38.9 ± 19.8 | 0.8896 |
| G3 | 47 | 78.4 ± 14.9 | 44 | 67.4 ± 24.0 | 28 | 37.9 ± 25.9 | ||||
| Tumor location (n = 144) | Left | 87 | 76.8 ± 14.7 | 0.6438 | 82 | 73.9 ± 18.8 | 0.3217 | 52 | 38.2 ± 20.1 | 0.9777 |
| Rectum | 18 | 71.0 ± 21.2 | 18 | 68.0 ± 19.5 | 13 | 38.1 ± 23.8 | ||||
| Right | 39 | 77.9 ± 13.9 | 34 | 69.6 ± 21.4 | 26 | 39.6 ± 24.6 | ||||
| pT classification (n = 144) | pT1–2 | 38 | 77.5 ± 14.8 | 0.6978 | 36 | 71.9 ± 19.2 | 0.7806 | 24 | 34.8 ± 18.4 | 0.3177 |
| pT3–4 | 106 | 76.0 ± 15.7 | 98 | 72.1 ± 19.8 | 67 | 39.9 ± 22.8 | ||||
| pN classification (n = 144) | pN0 | 78 | 74.5 ± 17.6 | 0.495 | 75 | 72.4 ± 18.6 | 0.7753 | 50 | 37.7 ± 20.7 | 0.5982 |
| pN1–2 | 66 | 78.6 ± 12.3 | 59 | 71.6 ± 20.9 | 41 | 39.6 ± 23.3 | ||||
| pM classification (n = 144) | pM0 | 125 | 76.8 ± 15.5 | 0.1818 | 117 | 72.7 ± 19.3 | 0.2707 | 75 | 40.8 ± 21.7 | 0.0291 |
| pM1 | 19 | 73.8 ± 15.4 | 17 | 67.4 ± 21.6 | 16 | 28.1 ± 19.3 | ||||
| Venous invasion (n = 144) | Present | 27 | 76.2 ± 14.3 | 0.6017 | 25 | 71.1 ± 21.5 | 0.8807 | 18 | 36.4 ± 25.0 | 0.6367 |
| Negative | 117 | 76.4 ± 15.8 | 109 | 72.3 ± 19.2 | 73 | 39.1 ± 21.1 | ||||
| Lymphatic invasion (n = 144) | Present | 57 | 78.5 ± 12.8 | 0.4896 | 51 | 71.7 ± 21.3 | 0.5847 | 39 | 39.1 ± 24.3 | 0.7802 |
| Negative | 87 | 75.0 ± 17.0 | 83 | 72.3 ± 18.5 | 52 | 38.2 ± 19.9 | ||||
| Post-operative therapy (n = 144) | None | 57 | 76.1 ± 15.1 | 0.8771 | 55 | 75.5 ± 20.1 | 0.6674 | 34 | 34.4 ± 19.8 | 0.1828 |
| Treated | 87 | 76.5 ± 15.8 | 79 | 71.7 ± 19.3 | 57 | 41.1 ± 22.7 | ||||
| Tumor budding (10-in-10) (n = 144) | Low-grade | 78 | 75.1 ± 15.5 | 0.1876 | 71 | 75.3 ± 17.3 | 0.0894 | 39 | 46.3 ± 17.5 | 0.0024 |
| High-grade | 66 | 77.9 ± 15.4 | 63 | 68.5 ± 21.4 | 52 | 32.8 ± 23.0 | ||||
| Survival (n = 144) | HR (95%CI) | 144 | 0.998 (0.983–1.014) | 0.7983 | 134 | 0.991 (0.978–1.004) | 0.1805 | 91 | 0.996 (0.981–1.011) | 0.5771 |